Intervention Protocol

Pharmaceutical policies: effects on rational drug use

  1. Morten Aaserud1,*,
  2. Astrid Austvoll-Dahlgren2,
  3. Heidrun Sturm3,
  4. Jan Peter Kösters4,
  5. Suzanne Hill5,
  6. Curt Furberg6,
  7. Roberto Grilli7,
  8. David A Henry8,
  9. Andrew D Oxman9,
  10. Craig R Ramsay10,
  11. Dennis Ross-Degnan11,
  12. Stephen B Soumerai12

Editorial Group: Cochrane Effective Practice and Organisation of Care Group

Published Online: 19 APR 2006

DOI: 10.1002/14651858.CD004397.pub2

How to Cite

Aaserud M, Austvoll-Dahlgren A, Sturm H, Kösters JP, Hill S, Furberg C, Grilli R, Henry DA, Oxman AD, Ramsay CR, Ross-Degnan D, Soumerai SB. Pharmaceutical policies: effects on rational drug use (Protocol). Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD004397. DOI: 10.1002/14651858.CD004397.pub2.

Author Information

  1. 1

    Norwegian Medicines Agency, Statens legemiddelverk, Oslo, Norway

  2. 2

    Norwegian Knowledge Centre for the Health Services, Oslo, Norway

  3. 3

    University Medical Center Tübingen, Comprehensive Cancer Center, Tübingen, Germany

  4. 4

    Rigshospitalet, 3343, Nordic Cochrane Centre, Copenhagen Ø, Denmark

  5. 5

    Faculty of Medicine & Health Sciences, The University of Newcastle, Department of Clinical Pharmacology, Newcastle, New South Wales, Australia

  6. 6

    Wake Forest University, Public Health Services, Winston-Salem, USA

  7. 7

    Agenzia Sanitaria Regionale, Bologna, Italy

  8. 8

    Institute of Clinical Evaluative Sciences, Toronto, Ontario, Canada

  9. 9

    Norwegian Knowledge Centre for the Health Services, Global Health Unit, Oslo, Norway

  10. 10

    University of Aberdeen, Health Services Research Unit, Division of Applied Health Sciences, Aberdeen, UK

  11. 11

    Harvard Medical School, Drug Policy Research Group, Dept. of Population Medicine, Boston, MA, USA

  12. 12

    Harvard Medical School, Department of Ambulatory Care and Prevention, Boston, MA, USA

*Morten Aaserud, Statens legemiddelverk, Norwegian Medicines Agency, Sven Oftedals vei 8, Oslo, NO-0950, Norway. morten.aaserud@legemiddelverket.no.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 19 APR 2006

SEARCH

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

Type your institution's name in the box below. If your institution is a Wiley customer, it will appear in the list of suggested institutions and you will be able to log in to access content. Some users may also log in directly via OpenAthens.

Please note that there are currently a number of duplicate entries in the list of institutions. We are actively working on fixing this issue and apologize for any inconvenience caused.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

Patient Access

Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.